- All site RSS

News

Skoltech, MIT reflect on first year of collaboration
Anniversary event celebrates international ties. Skoltech President Edward F. Crawley, Ford Professor of Engineering at MIT, meets with students. Photo courtesy of Tom Luly In late October, faculty and...

Russian tech hub Skolkovo in 2012 by the numbers: $97m in grants, 750 residents, 49 funds
Russian innovation center Skolkovo has announced its preliminary results of 2012, boasting several hundred new companies, more than a hundred intellectual property items and $97 million given to startups...

«Computer Vision Systems» in TOP 10 Best Russian Projects by version of the TOP Russian Start-Ups
Development of «Computer Vision Systems» – CVS Technology of gestures recognition entered the TOP 10 of the TOP 50 most outstanding and promising Russian innovative Start-Ups, having...

Fabless Design Center Project on 65/45 nm
ru.scribd.com/.../Fabless-Design-Project-65-45-nm

Russian Innovation Convention 2012 took place at the Skolkovo’s Hypercube
«Russian Innovation Convention 2012», со-organized by the Skolkovo’s Technopark, brought more than thousand participants and tens of high profile speakers from the sphere of innovation...

Protection Technology Research at SeedForum Moscow
On the 18th of December 2012 first Skolkovo building “Hypercube” welcomed Russian Innovative Convention and SeedForum Moscow. SeedForum is authoritative international event dedicated for mutual...

StLase Modular Laser System Wins 2013 IF Product Design Award
The modular laser system stLase (represented in the global market under the brand name Alta ®), developed by Photonics, invested by Maxwell Biotech Venture Fund and RVC Seed Fund, together with U.S...

Maxwell Biotech Venture Fund’s Portfolio Company Infectex Enrolls First Patients in Pivotal Clinical Trial of SQ109 for Multi-Drug Resistant Tuberculosis (MDR-TB)
Infectex, a Russian biotech company in Maxwell Biotech Venture Fund’s portfolio announced today enrollment of the first patients in its Phase IIb-III clinical trial of SQ109 for MDR-TB. Infectex...

Maxwell Biotech Venture Fund’s Portfolio Company Infectex Enrolls First Patients in Pivotal Clinical Trial of SQ109 for Multi-Drug Resistant Tuberculosis (MDR-TB)
Infectex, a Russian biotech company in Maxwell Biotech Venture Fund’s portfolio announced today enrollment of the first patients in its Phase IIb-III clinical trial of SQ109 for MDR-TB. Infectex...